KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) Invested Capital (2016 - 2025)

Historic Invested Capital for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to $1.3 billion.

  • Emergent BioSolutions' Invested Capital rose 549.12% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 549.12%. This contributed to the annual value of $1.2 billion for FY2024, which is 2206.63% down from last year.
  • Emergent BioSolutions' Invested Capital amounted to $1.3 billion in Q3 2025, which was up 549.12% from $1.2 billion recorded in Q2 2025.
  • Over the past 5 years, Emergent BioSolutions' Invested Capital peaked at $2.8 billion during Q4 2022, and registered a low of $1.2 billion during Q4 2024.
  • In the last 5 years, Emergent BioSolutions' Invested Capital had a median value of $1.9 billion in 2023 and averaged $1.9 billion.
  • Its Invested Capital has fluctuated over the past 5 years, first skyrocketed by 2760.74% in 2021, then tumbled by 4582.55% in 2023.
  • Over the past 5 years, Emergent BioSolutions' Invested Capital (Quarter) stood at $2.5 billion in 2021, then rose by 13.83% to $2.8 billion in 2022, then crashed by 45.83% to $1.5 billion in 2023, then dropped by 22.07% to $1.2 billion in 2024, then rose by 7.85% to $1.3 billion in 2025.
  • Its Invested Capital was $1.3 billion in Q3 2025, compared to $1.2 billion in Q2 2025 and $1.3 billion in Q1 2025.